Labeling Changes for Topiramate (Topamax) and Doripenem (Doribax)

• Autores: Diane S. Aschenbrenner
• Localización: American Journal of Nursing, ISSN 0002-936X, Vol. 114, Nº. 7, 2014, págs. 22-23
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • * The Food and Drug Administration (FDA) has approved the antiepileptic drug topiramate (Topamax) for a new indication, the prevention of migraines in adolescents ages 12 to 17.

    * The FDA has added a new warning to the labeling of the antibiotic doripenem (Doribax), which now warns that the drug increases the risk of death if used to treat ventilator-associated bacterial pneumonia, an off-label use.